You searched for "haemostatic"
Prostate alpha-1 receptors: what is new?
This article from the west of Germany will be of interest to many of us who use alpha-blockers for bladder outflow symptoms. The classic model of understanding of alpha receptors has been challenged recently. Further models have been identified, including...
Impact of prostatic apex in continence after RARP
This article investigates the impact of prostatic apical shape from preoperative magnetic resonance imaging (MRI) on early recovery of urinary continence after robot-assisted radical prostatectomy (RARP). It is a retrospective study of 1011 patients at a tertiary centre. Patients were...
Prostatic artery embolisation versus sham
Randomised trials with use of sham is uncommon in the surgical literature, which makes this paper more interesting. Many different treatments are available for treating lower urinary tract symptoms / benign prostatic hyperplasia (LUTS / BPH). Prostatic artery embolisation (PAE)...
Male LUTS: where do we stand?
Patients’ preferences and expectations depend on cultural, geographical, economic and national factors. Data from different countries should be interpreted with caution when applied to the individual patient. Patients rarely seek help for benign prostatic obstruction (BPO) unless urinary retention occurs,...
What is the significance of prostatic calcification?
This prospective study on men undergoing transrectal ultrasonography (TRUS) biopsies was performed to evaluate the prevalence and to classify prostatic calcification (PCalc) on TRUS and correlate the findings with histology. Images of the prostate were saved at three defined regions:...
BPH therapy: how to find one’s way through the maze?
This communication is from the Young Academic Urologists (YAU) group of the European Association of Urologists (EAU). A purpose-built questionnaire of current practice was sent to 2000 members, of which 637 responded (68% were aged 50 or younger). Alpha blockers...
Prostatic urethral lift for obstructive median lobes: 12-month results of the MedLift study
As the various new BPH therapies try and mark out their role in the management of the condition, this is an interesting and useful addition to the literature. Patients were clinically screened for an obstructive median lobe on cystoscopy, which...Immunotherapy in renal cancer
Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...Prostate abscess
Prostate abscess (PA) is a relatively uncommon clinical condition which is often difficult to diagnose because clinical symptoms are non-specific. It may be associated with a significant fatality rate, estimated to be between 3% and 30%, which may reflect its...MOWOOT II Intestinal Transit Management System
MOWOOT II is an intermittent colonic exo-peristaltic therapy system for intestinal transit disorders, such as slow transit constipation. MOWOOT II utilises advanced pneumatic technology to treat and prevent chronic constipation without laxatives, enemas...
PDE5I in LUTS – how do they work – no proof yet
Phosphodiesterase type 5 (PDE5) inhibitors used in erectile dysfunction (ED) have been shown to improve lower urinary tract symptoms (LUTS) as well. The mechanism is not well understood. One of the hypotheses for benign prostatic hyperplasia (BPH) – LUTS is...
